Novartis Unit Sandoz Announced Earlier: Marketing Authorization Applications For Proposed Biosimilar Denosumab Accepted By EMA
Portfolio Pulse from Charles Gross
Sandoz, a unit of Novartis, announced that the European Medicines Agency (EMA) has accepted the marketing authorization applications for proposed biosimilar denosumab for regulatory review.
May 25, 2023 | 8:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novartis' unit Sandoz receives EMA acceptance for marketing authorization applications of proposed biosimilar denosumab.
The EMA's acceptance of the marketing authorization applications for the proposed biosimilar denosumab is a positive development for Novartis' unit Sandoz. This could potentially lead to increased revenue and market share for the company in the biosimilar market, positively impacting Novartis' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100